Merck & Co. already failed twice in its quest to develop a vaccine, but now says an experimental antiviral pill for COVID-19 reduces the risk of hospitalization and even death by half of the people infected with the virus when given early.
During clinical trial, Molnupiravir, was given to the patients recently infected with COVID-19 twice a day and the results were outstanding according to the company.
Within the next two weeks, Merck will ask health officials for emergency use authorization for the drug in the US and around the world.
The liberal media is touting the news but downplayed and lied about hydroxychloroquine (HCQ) and Ivermectin for over a year now. This is despite HCQ’s 75% success rate in early treatment mortality tests and Ivermectin’s solid results in India and elsewhere.
It’s almost like the government, Dr. Fauci and the American medical community were lying to the public all along?
Weird, huh?
So when will we see these killers sent to prison?
More from CBS News:
Merck and its partner, Ridgeback Biotherapeutics, said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and deaths as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered at higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.
Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.The results were released by the company and have not been peer reviewed. Merck said it plans to present them at a future medical meeting.
“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck research. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”
Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.
Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.
According to a report from Bloomberg, Merck & Co. had already failed twice in its pursuit to develop a vaccine and scrapped a drug it acquired through a $425 million deal months prior.
Talking about early treatment, Ivermectin has proven its efficacy worldwide and yet there’s still a media blackout. The Gateway Pundit previously reported about the success of Ivermectin in Uttar Pradesh in India when given early to the recently diagnosed with COVID-19 and now the said state is COVID-19 free.
COVID cases are plummeting in India thanks to new rules that promote Ivermectin and hydroxychloroquine to its massive population. The 33 districts in Uttar Pradesh, India have now become free from COVID-19 government informed on Sep. 10. The recovery rate has increased up to 98.7% proving the effectiveness of IVERMECTIN as part of the “Uttar Pradesh Covid Control Model.” Of course there’s a media blackout, the media won’t mention that Ivermectin is being used for the treatment of COVID-19.
Uttar Pradesh is the leading state in India to use Ivermectin as early and preventatively in all family contacts. And this state is one of the five lowest COVID cases of all states in India despite having only a low vaccination rate compared to the USA. Read more:
The post Merck & Co. Cheers Experimental Antiviral Pill for COVID-19 That Cuts Death and Hospitalization By Half – Sort of Like HCQ and Ivermectin appeared first on The Gateway Pundit.
from The Gateway Pundit https://ift.tt/3A9Ckys
No comments:
Post a Comment